vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and STEM, INC. (STEM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $47.1M, roughly 1.2× STEM, INC.). STEM, INC. runs the higher net margin — -33.9% vs -83.0%, a 49.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -15.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 36.1%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
RYTM vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $47.1M |
| Net Profit | $-47.5M | $-16.0M |
| Gross Margin | 91.6% | 48.9% |
| Operating Margin | -82.2% | -17.7% |
| Net Margin | -83.0% | -33.9% |
| Revenue YoY | 36.9% | -15.6% |
| Net Profit YoY | -9.6% | 68.8% |
| EPS (diluted) | $-0.73 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $47.1M | ||
| Q3 25 | $51.3M | $38.2M | ||
| Q2 25 | $48.5M | $38.4M | ||
| Q1 25 | $32.7M | $32.5M | ||
| Q4 24 | $41.8M | $55.8M | ||
| Q3 24 | $33.3M | $29.3M | ||
| Q2 24 | $29.1M | $34.0M | ||
| Q1 24 | $26.0M | $25.5M |
| Q4 25 | $-47.5M | $-16.0M | ||
| Q3 25 | $-52.9M | $-23.8M | ||
| Q2 25 | $-46.6M | $202.5M | ||
| Q1 25 | $-49.5M | $-25.0M | ||
| Q4 24 | $-43.3M | $-51.1M | ||
| Q3 24 | $-43.6M | $-148.3M | ||
| Q2 24 | $-32.3M | $-582.3M | ||
| Q1 24 | $-141.4M | $-72.3M |
| Q4 25 | 91.6% | 48.9% | ||
| Q3 25 | 89.3% | 35.5% | ||
| Q2 25 | 88.6% | 33.4% | ||
| Q1 25 | 88.8% | 32.4% | ||
| Q4 24 | 90.9% | -4.4% | ||
| Q3 24 | 88.5% | 21.2% | ||
| Q2 24 | 89.9% | 27.6% | ||
| Q1 24 | 89.2% | -95.0% |
| Q4 25 | -82.2% | -17.7% | ||
| Q3 25 | -102.6% | -33.6% | ||
| Q2 25 | -93.4% | -34.8% | ||
| Q1 25 | -143.7% | -65.0% | ||
| Q4 24 | -98.6% | -84.4% | ||
| Q3 24 | -132.0% | -493.2% | ||
| Q2 24 | -139.2% | -1705.5% | ||
| Q1 24 | -538.7% | -267.0% |
| Q4 25 | -83.0% | -33.9% | ||
| Q3 25 | -103.1% | -62.2% | ||
| Q2 25 | -96.1% | 527.8% | ||
| Q1 25 | -151.4% | -76.9% | ||
| Q4 24 | -103.6% | -91.6% | ||
| Q3 24 | -131.2% | -506.3% | ||
| Q2 24 | -110.9% | -1712.6% | ||
| Q1 24 | -544.4% | -283.9% |
| Q4 25 | $-0.73 | $-4.40 | ||
| Q3 25 | $-0.82 | $-2.84 | ||
| Q2 25 | $-0.75 | $-1.79 | ||
| Q1 25 | $-0.81 | $-0.15 | ||
| Q4 24 | $-0.71 | $-15.29 | ||
| Q3 24 | $-0.73 | $-18.24 | ||
| Q2 24 | $-0.55 | $-71.81 | ||
| Q1 24 | $-2.35 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $-249.4M |
| Total Assets | $480.2M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $48.9M | ||
| Q3 25 | $416.1M | $43.1M | ||
| Q2 25 | $291.0M | $40.8M | ||
| Q1 25 | $314.5M | $58.6M | ||
| Q4 24 | $320.6M | $56.3M | ||
| Q3 24 | $298.4M | $75.4M | ||
| Q2 24 | $319.1M | $89.6M | ||
| Q1 24 | $201.2M | $112.8M |
| Q4 25 | $139.1M | $-249.4M | ||
| Q3 25 | $148.8M | $-235.7M | ||
| Q2 25 | $-11.9M | $-214.1M | ||
| Q1 25 | $18.9M | $-417.5M | ||
| Q4 24 | $21.7M | $-398.4M | ||
| Q3 24 | $11.2M | $-344.1M | ||
| Q2 24 | $39.3M | $-203.2M | ||
| Q1 24 | $61.6M | $371.6M |
| Q4 25 | $480.2M | $308.9M | ||
| Q3 25 | $506.9M | $362.6M | ||
| Q2 25 | $372.7M | $379.2M | ||
| Q1 25 | $386.7M | $405.1M | ||
| Q4 24 | $392.3M | $437.4M | ||
| Q3 24 | $363.6M | $537.8M | ||
| Q2 24 | $381.8M | $691.5M | ||
| Q1 24 | $258.7M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $8.2M | ||
| Q3 25 | $-26.6M | $11.4M | ||
| Q2 25 | $-23.3M | $-21.3M | ||
| Q1 25 | $-40.4M | $8.5M | ||
| Q4 24 | $-18.8M | $-14.7M | ||
| Q3 24 | $-25.2M | $-9.4M | ||
| Q2 24 | $-29.1M | $-11.9M | ||
| Q1 24 | $-40.7M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
